Fennec Pharmaceuticals Inc (NASDAQ: FENC) has reported E.P.S. of $0.47 for its first fiscal quarter (ending March 31) versus $-0.23 for the same period a year ago. This result exceeded the consensus estimate of $0.44 by $0.03. For the latest four quarters through March 31, E.P.S. were $0.09 versus $-0.99 for the same period a year ago.
Recent Price Action
Fennec Pharmaceuticals Inc (NASDAQ: FENC) stock closed at $7.34 on 5/14/24 after a major decline of -26.7%. Moreover, this decline was accompanied by exceptionally high trading volume at 2616% of normal. The stock has been exceptionally strong relative to the market over the last nine months but has declined -19.3% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, FENC is expected to be Value Creation neutral.
Fennec Pharmaceuticals is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment